| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
ARS Pharmaceuticals (NASDAQ:SPRY) will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ARS Pharmaceuticals to report an earnings per share (EPS) of $-0.47.
The market awaits ARS Pharmaceuticals's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
During the last quarter, the company reported an EPS beat by $0.01, leading to a 0.79% increase in the share price on the subsequent day.
Here's a look at ARS Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.36 | -0.12 | -0.15 | -0.12 |
| EPS Actual | -0.35 | 0.48 | -0.20 | -0.13 |
| Price Change % | 1.0% | -14.000000000000002% | 0.0% | -2.0% |
Shares of ARS Pharmaceuticals were trading at $16.38 as of August 11. Over the last 52-week period, shares are up 27.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for ARS Pharmaceuticals visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: SPRY
